Tuesday, Aug. 24, 2021 : Issue #1161 |
|
Letter from the Editor
 Today I had 8 Doctor of Pharmacy Candidates on a Teams call to talk about diabetes medications. The goal was to take these students from classroom recitation of information to the real world, where they have to explain things to patients, not professors. As you can guess there was a lot of discussion of side effects, regardless of how minute, and the use of big words like glyconeogenesis, in their explanations. After the first couple of presentations they got the hang of it, and for the most part did a great job explaining the medications without scaring off the patients. One of the other things they had to present was pricing, as we all know that usually influences most drug purchases long term.
One of the interns pointed out that Ertugliflozin had a cash price about 40% lower than the other SGLT-2 inhibitors. The consensus was that the drug must not be as good as the others in the class.
That was when Andy Dao, PharmD Candidate, University of South Florida Taneja College of Pharmacy, shared an article he had prepared for this week's newsletter that reviewed the Vertis CV trial and proved that this drug was just as effective as the others in class, for patients with type 2 diabetes and ASCVD.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
